(Q45733502)

15 December 2017

Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial (English)

1 reference

15 December 2017

1 reference

1 reference

1

1 reference

15 December 2017

4

1 reference

15 December 2017

F Imbert-Bismut

2

1 reference

15 December 2017

V Ratziu

3

1 reference

15 December 2017

C Jardel

5

1 reference

15 December 2017

J Moussalli

6

1 reference

15 December 2017

D Messous

7

1 reference

15 December 2017

F Degos

8

1 reference

15 December 2017

GERMED cyt04 group

9

1 reference

15 December 2017

1 March 2002

1 reference

Journal of Viral Hepatitis

15 December 2017

1 reference

15 December 2017

9

1 reference

15 December 2017

128-133

1 reference

15 December 2017

2

1 reference

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

15 December 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00341.X

Evaluation of fibrosis and hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00341.X

Fibrosis in patients with chronic hepatitis C: detection and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00341.X

Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00341.X

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00341.X

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00341.X

Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00341.X

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00341.X

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00341.X

Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00341.X

Appropriateness of liver biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00341.X

10.1046/J.1365-2893.2002.00341.X

21 January 2018

Identifiers

DOI

1 reference

15 December 2017

1 reference